Cerus' Phase 3 trial for INTERCEPT RBCs enrolling a broader patient population requiring RBC transfusion for acute and chronic anemia. Cerus anticipates initiating a modular PMA application to the FDA ...
The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA ...
Cerus’ Notified Body, TÜV-SÜD, has completed the review of the clinical module for the CE Mark submission for INTERCEPT Red Blood Cells (RBCs) CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation ...
Hosted on MSN
Cerus targets $194M-$200M revenue in 2025 with double-digit growth and new product launches
CEO Obi Greenman highlighted Cerus Corporation's position as a leader in transfusion medicine, with INTERCEPT products becoming the standard-of-care in over 40 countries. Approximately 20 million ...
CONCORD, Calif. & DENVER--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that Bonfils Blood Center has signed a three-year purchase agreement for the INTERCEPT Blood System for ...
Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells CONCORD, Calif.--(BUSINESS WIRE)-- ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product ...
Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT The new BARDA contract will be funded in whole or in part with federal funds from the Department of Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback